NextCure, Inc. (NXTC) AI Dilution Summary

Cash was $20,088,000 at 2026-06-30 against estimated monthly burn of $3,238,333. After that balance-sheet date, the company received $500,000 net on 2026-07-31 from selling Beltsville facility assets to Xcellon Biologics, LLC. That was an asset sale, not an equity raise. Cash outflows recorded after that date include a $760,000 lease termination fee dated 2026-07-31.